Professor Phil Darcy is currently a Group Leader and Head of the Cancer Immunology Faculty at the Peter MacCallum Cancer Centre. He received an honorary appointment in 2018 as Professor at the University of Melbourne, Dept of Clinical Pathology. He was awarded a National Health and Medical Research Council L3 Investigator Fellowship in 2024 and received a Fellowship of the Australian Academy of Health and Medical Sciences in 2022. His work has focused on developing CAR T cell therapy for cancer in preclinical mouse models and translating this into patients. He led the first CAR T cell trial in Australia in 2013 at the Peter MacCallum Cancer Centre in patients with acute myeloid leukaemi. More recently his studies have involved using new gene editing technologies to enhance CAR T cell efficacy. He has published his work in premier scientific journals including a recent paper in Nature (2024).